Aktie·LSE·£
Codexis, Inc. specializes in the invention, advancement, and commercialization of enzymes and various other proteins. Their diverse portfolio encompasses biocatalyst solutions, chemical intermediates designed for subsequent processing, and specialized Codex biocatalyst panels and kits that empower clients to conduct effective chemistry screening. Additionally, the company delivers expertise in biocatalyst screening and protein engineering services. A cornerstone of their operations is the proprietary CodeEvolver protein engineering technology platform. This platform is instrumental in crafting and deploying biocatalysts that facilitate chemical transformations, significantly boosting the efficiency and output of manufacturing processes. Beyond manufacturing applications, CodeEvolver also plays a vital role in identifying novel biotherapeutic drug candidates for specific human ailments, alongside its use in molecular biology and the development of in vitro diagnostic enzymes. Codexis markets its offerings directly to pharmaceutical manufacturers across the United States and Europe, leveraging its dedicated sales and business development teams. Established in 2002, the company maintains its headquarters in Redwood City, California.
Sehen Sie den Preis von 0I0X.L live auf Ihrem physischen Bildschirm. Alarme via iOS- und Android-App.
